argenx SE (NASDAQ:ARGX) Shares Acquired by China Universal Asset Management Co. Ltd.

China Universal Asset Management Co. Ltd. boosted its position in argenx SE (NASDAQ:ARGX - Free Report) by 388.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,719 shares of the company's stock after acquiring an additional 2,958 shares during the period. China Universal Asset Management Co. Ltd.'s holdings in argenx were worth $1,415,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Parkside Financial Bank & Trust acquired a new position in argenx in the third quarter valued at about $28,000. KB Financial Partners LLC lifted its stake in argenx by 112.5% in the first quarter. KB Financial Partners LLC now owns 85 shares of the company's stock valued at $27,000 after buying an additional 45 shares during the period. FNY Investment Advisers LLC acquired a new stake in shares of argenx during the fourth quarter worth about $38,000. Nkcfo LLC raised its position in shares of argenx by 22.1% during the third quarter. Nkcfo LLC now owns 116 shares of the company's stock worth $57,000 after purchasing an additional 21 shares during the period. Finally, Captrust Financial Advisors raised its position in shares of argenx by 116.7% during the first quarter. Captrust Financial Advisors now owns 143 shares of the company's stock worth $45,000 after purchasing an additional 77 shares during the period. Institutional investors own 60.32% of the company's stock.

Analysts Set New Price Targets

ARGX has been the subject of a number of research reports. Piper Sandler increased their price objective on argenx from $518.00 to $522.00 and gave the stock an "overweight" rating in a report on Friday, January 26th. Evercore ISI decreased their price objective on argenx from $594.00 to $436.00 and set an "outperform" rating for the company in a report on Thursday, December 21st. Truist Financial increased their price objective on argenx from $370.00 to $440.00 and gave the stock a "buy" rating in a report on Tuesday, March 5th. Wells Fargo & Company increased their price objective on argenx from $472.00 to $478.00 and gave the stock an "overweight" rating in a report on Tuesday, February 20th. Finally, Stifel Nicolaus increased their price objective on argenx from $557.00 to $560.00 and gave the stock a "buy" rating in a report on Monday, December 18th. One analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $530.74.

argenx Stock Performance

NASDAQ:ARGX traded down $11.61 during mid-day trading on Thursday, hitting $386.88. 144,711 shares of the stock were exchanged, compared to its average volume of 338,689. The stock has a market capitalization of $22.94 billion, a price-to-earnings ratio of -75.27 and a beta of 0.65. The firm's 50-day simple moving average is $390.39 and its 200 day simple moving average is $430.50. argenx SE has a fifty-two week low of $327.73 and a fifty-two week high of $550.76.

argenx (NASDAQ:ARGX - Get Free Report) last released its quarterly earnings results on Thursday, February 29th. The company reported ($1.68) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.45). The firm had revenue of $417.84 million for the quarter, compared to analyst estimates of $378.60 million. argenx had a negative return on equity of 16.97% and a negative net margin of 23.26%. During the same period in the previous year, the business posted ($0.70) earnings per share. On average, analysts predict that argenx SE will post -2 EPS for the current fiscal year.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, France, Canada, the United Kingdom, and Italy. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, pemphigus foliaceus, chronic inflammatory demyelinating polyneuropathy, bullous pemphigoid, and idiopathic inflammatory myopathy; and ENHANZE SC.